# An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy

> **NCT07631871** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Haihua Yuan** · enrollment: 10 (estimated)

## Conditions studied

- Neoplasms
- Solid Tumors
- HER2 Positive Solid Tumor
- Endometrial Neoplasm
- Urothelial Carcinoma (UC)
- Pancreatic Neoplasms
- Colorectal Neoplasms
- Head and Neck Neoplasms
- Cervical Neoplasms
- Ovarian Neoplasms

## Interventions

- **DRUG:** Zanidatamab

## Key facts

- **NCT ID:** NCT07631871
- **Lead sponsor:** Haihua Yuan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07631871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07631871, "An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07631871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*